The UAB Neurofibromatosis Clinic is looking to enroll adults with Neurofibromatosis Type 1 (NF1) for a clinical trial targeting cutaneous neurofibromas using the investigational drug called selumetinib. Cutaneous neurofibromas are the benign tumors on or in the skin that are common in adults with NF1. Study participants will take selumetinib by mouth as capsules every 12 hours for 24 cycles (one cycle equals 28 days). This study lasts approximately 2 years, unless significant side-effects develop. You may find more information regarding this clinical trial at here.

Clinical Trials Information 

The UAB Neurofibromatosis Clinic provides comprehensive, integrated care for children and adults with all forms of neurofibromatosis including NF1, NF2, and schwannomatosis. Led by experienced specialists Bruce Korf, M.D., Ph.D., and Lane Rutledge, M.D., who have extensive expertise in caring for patients of all ages with all forms of NF, the clinic offers a multidisciplinary approach to care that gives patients access to a range of other specialists who collaborate in the treatment and management of NF and its complications. Experienced genetic counselors and nurses also provide patients and families with assistance and support in managing the lifelong, medical, psychological, and social implications of an NF diagnosis.